Prediction of hyperkalemia associated with prolonged treatment with captopril by glucose-induced acute serum potassium changes.
The effect on potassium levels of short-term (5-10 days) and "prolonged" (4 weeks) captopril therapy were compared. No consistent changes during short-term treatment were found and the elevations in serum potassium associated with prolonged treatment could not be predicted on the basis of short-term changes. However, a definite correlation was found between glucose-induced serum potassium alterations (in the course of glucose tolerance test) during short-term captopril administration and elevations in baseline serum potassium during prolonged treatment In the patients with glucose-induced paradoxical serum potassium elevations, baseline serum potassium levels increased more markedly during prolonged captopril therapy than in patients with the opposite glucose-induced changes.
D000450:Aldosterone / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000009:adverse effects* / Q000627:therapeutic use; D005947:Glucose; D005951:Glucose Tolerance Test; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced / Q000175:diagnosis*; D006973:Hypertension / Q000188:drug therapy; D007700:Kinetics; D011188:Potassium / Q000097:blood*; D011392:Proline / Q000031:analogs & derivatives*
D000450:Aldosterone; D011392:Proline; D002216:Captopril; D005947:Glucose; D011188:Potassium